Inhaled corticosteroids for chronic obstructive pulmonary disease-the shifting treatment paradigm

Morven Wilkie, Simon Finch, Stuart Schembri (Lead / Corresponding author)

    Research output: Contribution to journalReview article

    12 Citations (Scopus)
    159 Downloads (Pure)

    Abstract

    Chronic obstructive pulmonary disease (COPD) guidelines suggest using inhaled corticosteroids (ICS) in patients with severe airflow limitation or those at high risk of exacerbations. This recommendation is based on evidence demonstrating that ICS, especially when prescribed in fixed-dose combinations (FDC) with long-acting β2 agonists (LABA), improve quality of life (QoL), decrease exacerbations and hospitalisations, and have been associated with a trend towards a reduction in all-cause mortality. Audit shows that routine prescribing practice frequently uses inhaler therapies outside current guidelines recommendations; severe to very severe disease constitutes about 20% of all COPD patients, but up to 75% of COPD patients are prescribed an ICS, with significant numbers given ICS/LABA as first-line maintenance therapy. The role of ICS in the treatment paradigm for COPD is changing, driven by the growing evidence of increased risk of pneumonia, and the introduction of a new class of FDC; LABA and long-acting muscarinic antagonists (LAMA), which simplify dual bronchodilation and present a plausible alternative therapy. As the evidence base for dual therapy bronchodilation expands, it is likely that maximal bronchodilation will move up the treatment algorithm and ICS reserved for those with more severe disease who are not controlled on dual therapy. This change has already manifested in local COPD algorithms, such as those at Tayside, and represents a significant change in recommended prescribing practice. This review reassesses the role of ICS in the shifting treatment paradigm, in the context of alternative treatment options that provide maximal bronchodilation.

    Original languageEnglish
    Article number582-590
    Number of pages9
    JournalCOPD
    Volume12
    Issue number5
    Early online date16 Mar 2015
    DOIs
    Publication statusPublished - 2015

    Fingerprint

    Chronic Obstructive Pulmonary Disease
    Adrenal Cortex Hormones
    Therapeutics
    Guidelines
    Muscarinic Antagonists
    Nebulizers and Vaporizers
    Complementary Therapies
    Pneumonia
    Hospitalization
    Quality of Life
    Mortality

    Keywords

    • Chronic obstructive pulmonary disease
    • dual bronchodilation
    • inhaled corticosteroids
    • pneumonia

    Cite this

    Wilkie, Morven ; Finch, Simon ; Schembri, Stuart. / Inhaled corticosteroids for chronic obstructive pulmonary disease-the shifting treatment paradigm. In: COPD. 2015 ; Vol. 12, No. 5.
    @article{2e9bf02bfef34c749ae2327704054c66,
    title = "Inhaled corticosteroids for chronic obstructive pulmonary disease-the shifting treatment paradigm",
    abstract = "Chronic obstructive pulmonary disease (COPD) guidelines suggest using inhaled corticosteroids (ICS) in patients with severe airflow limitation or those at high risk of exacerbations. This recommendation is based on evidence demonstrating that ICS, especially when prescribed in fixed-dose combinations (FDC) with long-acting β2 agonists (LABA), improve quality of life (QoL), decrease exacerbations and hospitalisations, and have been associated with a trend towards a reduction in all-cause mortality. Audit shows that routine prescribing practice frequently uses inhaler therapies outside current guidelines recommendations; severe to very severe disease constitutes about 20{\%} of all COPD patients, but up to 75{\%} of COPD patients are prescribed an ICS, with significant numbers given ICS/LABA as first-line maintenance therapy. The role of ICS in the treatment paradigm for COPD is changing, driven by the growing evidence of increased risk of pneumonia, and the introduction of a new class of FDC; LABA and long-acting muscarinic antagonists (LAMA), which simplify dual bronchodilation and present a plausible alternative therapy. As the evidence base for dual therapy bronchodilation expands, it is likely that maximal bronchodilation will move up the treatment algorithm and ICS reserved for those with more severe disease who are not controlled on dual therapy. This change has already manifested in local COPD algorithms, such as those at Tayside, and represents a significant change in recommended prescribing practice. This review reassesses the role of ICS in the shifting treatment paradigm, in the context of alternative treatment options that provide maximal bronchodilation.",
    keywords = "Chronic obstructive pulmonary disease, dual bronchodilation, inhaled corticosteroids, pneumonia",
    author = "Morven Wilkie and Simon Finch and Stuart Schembri",
    year = "2015",
    doi = "10.3109/15412555.2014.995288",
    language = "English",
    volume = "12",
    journal = "COPD",
    issn = "1541-2555",
    publisher = "Taylor & Francis",
    number = "5",

    }

    Inhaled corticosteroids for chronic obstructive pulmonary disease-the shifting treatment paradigm. / Wilkie, Morven; Finch, Simon; Schembri, Stuart (Lead / Corresponding author).

    In: COPD, Vol. 12, No. 5, 582-590, 2015.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - Inhaled corticosteroids for chronic obstructive pulmonary disease-the shifting treatment paradigm

    AU - Wilkie, Morven

    AU - Finch, Simon

    AU - Schembri, Stuart

    PY - 2015

    Y1 - 2015

    N2 - Chronic obstructive pulmonary disease (COPD) guidelines suggest using inhaled corticosteroids (ICS) in patients with severe airflow limitation or those at high risk of exacerbations. This recommendation is based on evidence demonstrating that ICS, especially when prescribed in fixed-dose combinations (FDC) with long-acting β2 agonists (LABA), improve quality of life (QoL), decrease exacerbations and hospitalisations, and have been associated with a trend towards a reduction in all-cause mortality. Audit shows that routine prescribing practice frequently uses inhaler therapies outside current guidelines recommendations; severe to very severe disease constitutes about 20% of all COPD patients, but up to 75% of COPD patients are prescribed an ICS, with significant numbers given ICS/LABA as first-line maintenance therapy. The role of ICS in the treatment paradigm for COPD is changing, driven by the growing evidence of increased risk of pneumonia, and the introduction of a new class of FDC; LABA and long-acting muscarinic antagonists (LAMA), which simplify dual bronchodilation and present a plausible alternative therapy. As the evidence base for dual therapy bronchodilation expands, it is likely that maximal bronchodilation will move up the treatment algorithm and ICS reserved for those with more severe disease who are not controlled on dual therapy. This change has already manifested in local COPD algorithms, such as those at Tayside, and represents a significant change in recommended prescribing practice. This review reassesses the role of ICS in the shifting treatment paradigm, in the context of alternative treatment options that provide maximal bronchodilation.

    AB - Chronic obstructive pulmonary disease (COPD) guidelines suggest using inhaled corticosteroids (ICS) in patients with severe airflow limitation or those at high risk of exacerbations. This recommendation is based on evidence demonstrating that ICS, especially when prescribed in fixed-dose combinations (FDC) with long-acting β2 agonists (LABA), improve quality of life (QoL), decrease exacerbations and hospitalisations, and have been associated with a trend towards a reduction in all-cause mortality. Audit shows that routine prescribing practice frequently uses inhaler therapies outside current guidelines recommendations; severe to very severe disease constitutes about 20% of all COPD patients, but up to 75% of COPD patients are prescribed an ICS, with significant numbers given ICS/LABA as first-line maintenance therapy. The role of ICS in the treatment paradigm for COPD is changing, driven by the growing evidence of increased risk of pneumonia, and the introduction of a new class of FDC; LABA and long-acting muscarinic antagonists (LAMA), which simplify dual bronchodilation and present a plausible alternative therapy. As the evidence base for dual therapy bronchodilation expands, it is likely that maximal bronchodilation will move up the treatment algorithm and ICS reserved for those with more severe disease who are not controlled on dual therapy. This change has already manifested in local COPD algorithms, such as those at Tayside, and represents a significant change in recommended prescribing practice. This review reassesses the role of ICS in the shifting treatment paradigm, in the context of alternative treatment options that provide maximal bronchodilation.

    KW - Chronic obstructive pulmonary disease

    KW - dual bronchodilation

    KW - inhaled corticosteroids

    KW - pneumonia

    U2 - 10.3109/15412555.2014.995288

    DO - 10.3109/15412555.2014.995288

    M3 - Review article

    VL - 12

    JO - COPD

    JF - COPD

    SN - 1541-2555

    IS - 5

    M1 - 582-590

    ER -